Maria Fleseriu1, Beverly M K Biller2, Jérôme Bertherat3, Jacques Young4, Betul Hatipoglu5, Giorgio Arnaldi6, Paul O'Connell7, Miguel Izquierdo8, Alberto M Pedroncelli9, Rosario Pivonello10. 1. Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University, Portland, OR, USA. fleseriu@ohsu.edu. 2. Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA, USA. 3. Department of Endocrinology, Centre de Référence des Maladies Rares de la Surrénale, Hôpital Cochin, AP-HP, Université de Paris, Paris, France. 4. Department of Endocrinology, Assistance Publique Hôpitaux de Paris, Bicêtre Hospital, Paris Saclay University, Le Kremlin-Bicêtre, France. 5. CWRU School of Medicine, University Hospital Cleveland Medical Center, Cleveland, OH, USA. 6. Division of Endocrinology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy. 7. Novartis Ireland Limited, Dublin, Ireland. 8. Novartis Pharma AG, Basel, Switzerland. 9. Recordati AG, Basel, Switzerland. 10. Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy.
Abstract
BACKGROUND: Many patients with Cushing's disease (CD) require long-term medical therapy to control their hypercortisolism. In the core phase of a Phase II study (LINC 2; NCT01331239), osilodrostat normalized mean urinary free cortisol (mUFC) in 78.9% of patients with CD. Here, we report long-term efficacy and safety data for osilodrostat following completion of an optional extension to LINC 2. METHODS: Adult patients with CD were enrolled in a 22-week prospective Phase II study. Patients with mUFC ≤ upper limit of normal (ULN) or receiving clinical benefit at week 22 could enter the optional extension. The proportion of complete (mUFC ≤ ULN) or partial (mUFC > ULN but ≥ 50% decrease from baseline) mUFC responders was assessed over time. RESULTS: Sixteen of 19 enrolled patients entered the extension. Median (range) osilodrostat exposure from baseline to study end was 5.4 years (0.04-6.7); median (range) average dose was 10.6 mg/day (1.1-47.9). Overall response rate (complete and partial mUFC responders) was consistently ≥ 50%. Sustained control of most cardiovascular-related parameters was observed during the extension. The long-term safety profile was consistent with that reported during the core phase. Testosterone levels (females) decreased towards baseline levels during long-term follow-up, with no new or worsening cases of hirsutism during the extension. CONCLUSIONS: In the longest prospective study of a steroidogenesis inhibitor to date, osilodrostat provided sustained reductions in mUFC for up to 6.7 years of treatment, with no new safety signals emerging during the extension. These findings support osilodrostat as an effective long-term treatment for patients with CD.
BACKGROUND: Many patients with Cushing's disease (CD) require long-term medical therapy to control their hypercortisolism. In the core phase of a Phase II study (LINC 2; NCT01331239), osilodrostat normalized mean urinary free cortisol (mUFC) in 78.9% of patients with CD. Here, we report long-term efficacy and safety data for osilodrostat following completion of an optional extension to LINC 2. METHODS: Adult patients with CD were enrolled in a 22-week prospective Phase II study. Patients with mUFC ≤ upper limit of normal (ULN) or receiving clinical benefit at week 22 could enter the optional extension. The proportion of complete (mUFC ≤ ULN) or partial (mUFC > ULN but ≥ 50% decrease from baseline) mUFC responders was assessed over time. RESULTS: Sixteen of 19 enrolled patients entered the extension. Median (range) osilodrostat exposure from baseline to study end was 5.4 years (0.04-6.7); median (range) average dose was 10.6 mg/day (1.1-47.9). Overall response rate (complete and partial mUFC responders) was consistently ≥ 50%. Sustained control of most cardiovascular-related parameters was observed during the extension. The long-term safety profile was consistent with that reported during the core phase. Testosterone levels (females) decreased towards baseline levels during long-term follow-up, with no new or worsening cases of hirsutism during the extension. CONCLUSIONS: In the longest prospective study of a steroidogenesis inhibitor to date, osilodrostat provided sustained reductions in mUFC for up to 6.7 years of treatment, with no new safety signals emerging during the extension. These findings support osilodrostat as an effective long-term treatment for patients with CD.
Authors: Eliza B Geer; Ismat Shafiq; Murray B Gordon; Vivien Bonert; Alejandro Ayala; Ronald S Swerdloff; Laurence Katznelson; Yelena Lalazar; Ekaterina Manuylova; Karen J Pulaski-Liebert; John D Carmichael; Zeina Hannoush; Vijaya Surampudi; Michael S Broder; Dasha Cherepanov; Marianne Eagan; Jackie Lee; Qayyim Said; Maureen P Neary; Beverly M K Biller Journal: Endocr Pract Date: 2017-06-14 Impact factor: 3.443
Authors: Sara G Creemers; Richard A Feelders; Frank H de Jong; Gaston J H Franssen; Yolanda B de Rijke; Peter M van Koetsveld; Leo J Hofland Journal: J Clin Endocrinol Metab Date: 2019-08-01 Impact factor: 5.958
Authors: Maria Fleseriu; Richard Auchus; Irina Bancos; Anat Ben-Shlomo; Jerome Bertherat; Nienke R Biermasz; Cesar L Boguszewski; Marcello D Bronstein; Michael Buchfelder; John D Carmichael; Felipe F Casanueva; Frederic Castinetti; Philippe Chanson; James Findling; Mônica Gadelha; Eliza B Geer; Andrea Giustina; Ashley Grossman; Mark Gurnell; Ken Ho; Adriana G Ioachimescu; Ursula B Kaiser; Niki Karavitaki; Laurence Katznelson; Daniel F Kelly; André Lacroix; Ann McCormack; Shlomo Melmed; Mark Molitch; Pietro Mortini; John Newell-Price; Lynnette Nieman; Alberto M Pereira; Stephan Petersenn; Rosario Pivonello; Hershel Raff; Martin Reincke; Roberto Salvatori; Carla Scaroni; Ilan Shimon; Constantine A Stratakis; Brooke Swearingen; Antoine Tabarin; Yutaka Takahashi; Marily Theodoropoulou; Stylianos Tsagarakis; Elena Valassi; Elena V Varlamov; Greisa Vila; John Wass; Susan M Webb; Maria C Zatelli; Beverly M K Biller Journal: Lancet Diabetes Endocrinol Date: 2021-10-20 Impact factor: 32.069
Authors: Richard A Feelders; John Newell-Price; Rosario Pivonello; Lynnette K Nieman; Leo J Hofland; Andre Lacroix Journal: Lancet Diabetes Endocrinol Date: 2018-07-20 Impact factor: 32.069
Authors: Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin Journal: J Clin Endocrinol Metab Date: 2015-07-29 Impact factor: 5.958
Authors: Xavier Bertagna; Rosario Pivonello; Maria Fleseriu; Yiming Zhang; Paul Robinson; Ann Taylor; Catherine E Watson; Mario Maldonado; Amir H Hamrahian; Marco Boscaro; Beverly M K Biller Journal: J Clin Endocrinol Metab Date: 2013-12-11 Impact factor: 5.958
Authors: Maria Fleseriu; Rosario Pivonello; Jacques Young; Amir H Hamrahian; Mark E Molitch; Chikara Shimizu; Tomoaki Tanaka; Akira Shimatsu; Tracy White; Annie Hilliard; Chuan Tian; Nicholas Sauter; Beverly M K Biller; Xavier Bertagna Journal: Pituitary Date: 2016-04 Impact factor: 4.107